Nanopore Sequencing Pilot Aims to Cut Brain Tumor Diagnosis Time from Weeks to Hours
Newcastle’s pilot tests nanopore sequencing for rapid brain-tumor classification in the NHS. Early local data on 40 cases are promising but unpublished; the two-year multi-centre evaluation will determine scalability. Evidence remains at the feasibility stage pending larger diagnostic accuracy and outcome studies.
If the pilot meets pre-specified thresholds for sensitivity, specificity, and reliability, the test could shift from research use to standard NHS practice by 2028. Remaining questions include performance across rare subtypes, integration with intraoperative frozen-section workflows, and whether faster results translate into measurable survival or quality-of-life gains. A full diagnostic accuracy study with blinded central review and health-economic analysis is required before guideline committees can recommend routine adoption.
NHS England: ROBIN test concordance with standard panels exceeds 85% across 500 consecutive cases by end of 2027 pilot, triggering guideline review.
Sources (3)
- [1]Newcastle Hospitals Charity Pilot Report(https://www.newcastle-hospitals.nhs.uk/research)
- [2]Brain Tumour Charity Epidemiology Data 2023(https://www.thebraintumourcharity.org)
- [3]Oxford Nanopore ROBIN Validation Study(https://www.nature.com/articles/s41587-023-01980-5)